臨床研究等提出・公開システム

Date of registration	Dec. 04, 2025
Last modified on	Dec. 12, 2025
Trial ID	jRCT1070250109

Scientific Title	A Questionnaire-Based Study on the Actual Timing of Initiation of Japanese Encephalitis Vaccination
Public Title	A Questionnaire-Based Study on the Actual Timing of Initiation of Japanese Encephalitis Vaccination

Contact for Scientific Queries	Name	Shingo Uno
	Affiliation	KM Biologics Co., Ltd.
	Address	1314-1 Kyokushi Kawabe, Kikuchi-shi, Kumamoto 869-1298, Japan
	Telephone	+81-968-37-4079
	E-mail	uno-shi@kmbiologics.com
Contact for Public Queries	Name	Shingo Uno
	Affiliation	KM Biologics Co., Ltd.
	Address	1314-1 Kyokushi Kawabe, Kikuchi-shi, Kumamoto 869-1298, Japan
	Telephone	+81-968-37-4079
	E-mail	uno-shi@kmbiologics.com

Recruitment status	Recruiting

Anticipated date of first enrollment		Dec. 04, 2025
Target sample size		2700
Study Type		Observational
Key inclusion & exclusion criteria	Inclusion Criteria	1.Parents registered as panel members of Macromill Inc. who have children aged 4 to 6 years 2.Individuals who agreed, at the time of the survey, to allow anonymized survey results to be published in academic literature 3.Individuals who can confirm the month of the first dose of the Japanese encephalitis vaccine for their 4 to 6 year-old child using the Maternal and Child Health Handbook
	Exclusion Criteria	none
	Age Minimum	4age old over
	Age Maximum	7age old not
	Gender	Both
Health Condition(s) or Problem(s) Studied		Japanese Encephalitis
Health Condition(s) Code		N/A
Primary Outcome(s)		Proportion of individuals who initiated the first dose of Japanese encephalitis vaccine before age 3, nationwide and by regional block
Secondary Outcome(s)		Proportion of individuals who started vaccination before the age of 3 within each block (by prefecture) Annual trend in the proportion of individuals who started vaccination before the age of 3 (nationwide and by block) Proportion of reasons for not receiving vaccination among unvaccinated individuals Proportion of individuals who started vaccination before the age of 3 according to sources of information influencing vaccination decision (doctor's guidance, municipal notifications, SNS, vaccination schedule apps) (nationwide and by block) For cases where the source of information influencing vaccination decision was doctor's guidance: proportion of individuals who started vaccination before the age of 3 according to opportunities for guidance from medical institutions (during health checkups, after other vaccinations, during illness visits) (nationwide and by block) For cases where the source of information influencing vaccination decision was municipal notifications: proportion of individuals who started vaccination before the age of 3 according to timing of notifications from municipalities (during age 0, age 1, age 2, or after age 3) (nationwide and by block)

Primary Sponsor	KM Biologics Co., Ltd.

Secondary Sponsor

Secondary Sponsor

Name of Certified Review Board	KM Biologics Research Ethics Review Committee
Address	1314-1 Kyokushi Kawabe, Kikuchi-shi, Kumamoto 869-1298, Japan, Kumamoto
Telephone	+81-968-37-4079
E-Mail	rinsyoukenkyu@kmbiologics.com
Approval Status	Approval
Date of approval	Nov. 28, 2025

Plan to share IPD	No

Countries of Recruitment（Except Japan）	none

History of Changes

No	Publication date
2	Dec. 12, 2025	(this page)	Changes
1	Dec. 04, 2025	Detail

List of change history